<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027479</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO16-LO/METERMUS-IMC</org_study_id>
    <secondary_id>2016-A01323-48</secondary_id>
    <secondary_id>2016-R27</secondary_id>
    <nct_id>NCT03027479</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss</brief_title>
  <acronym>METERMUS-IMC</acronym>
  <official_title>Study of Differences in Skeletal Muscle Energy Metabolism Alterations in Women With Weight Loss and Ovarian and/or Endometrial Cancer Based on the Body Mass Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inserm U1069 - Team Nutrition, Growth and Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim is to study skeletal muscle metabolism alterations m√©taboliques associated with&#xD;
      weight loss in women with ovarian and/or endometrial cancer according to BMI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">July 16, 2019</completion_date>
  <primary_completion_date type="Actual">July 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of muscle mitochondrial bioenergetics according to BMI</measure>
    <time_frame>muscle biopsy realized during surgery</time_frame>
    <description>Measurement of muscle mitochondrial bioenergetics by high resolution oxygraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>on muscle biopsy</measure>
    <time_frame>muscle biopsy realized during surgery</time_frame>
    <description>Quantification of lipids on electron microscope&#xD;
Type of muscular fibers&#xD;
Analyze of gene expression and proteins involved in 1/ Mitochondrial metabolism 2/ lipid metabolism and 3/ muscular proteolysis by RTqPCR with SyBR Green and Western Blot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on white adipose tissue</measure>
    <time_frame>adipose tissue samples taken during surgery</time_frame>
    <description>adipose tissue composition (fatty acids quantification, sterols, steroids)&#xD;
RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profile and cytokines)&#xD;
RTqPCR analysis, western blot and immunohistochemical expression of markers of transformation into brown adipose tissue&#xD;
in specific milieu, in vitro experimentation on skeletal muscular cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on ovarian cancer tumor samples</measure>
    <time_frame>ovarian tumor biopsies realized during surgery</time_frame>
    <description>lipid composition (fatty acids quantification, sterols, steroids)&#xD;
RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profil and cytokines)&#xD;
culture of tumour cells to evaluate resistance to chemotherapy (platinum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on computerized tomography</measure>
    <time_frame>1 day of abdominal CT scan imaging procedure performed at diagnosis</time_frame>
    <description>assessment of body composition (fat and muscle compartments)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Weight Loss</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples</intervention_name>
    <description>Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Case group selection criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 years old and more&#xD;
&#xD;
          -  Ovarian and/or endometrial cancer&#xD;
&#xD;
          -  weight loss related to cancer (weight loss &gt; 5% weight in one month or 10% in 6&#xD;
             months)&#xD;
&#xD;
          -  Indication to therapeutic surgery&#xD;
&#xD;
          -  Women affiliated to social security scheme&#xD;
&#xD;
          -  Women who can understand French and able to sign Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unbalanced Diabetes&#xD;
&#xD;
          -  Chronic neuromuscular disorder&#xD;
&#xD;
          -  Any severe uncontrolled medical condition&#xD;
&#xD;
        Control group selection criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 years and more&#xD;
&#xD;
          -  Surgery Indication for a benign endometrial and/ or ovarian disease&#xD;
&#xD;
          -  Patient affiliated to social security scheme&#xD;
&#xD;
          -  Women who can understand French and able to sign Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unbalanced Diabetes&#xD;
&#xD;
          -  Chronic neuromuscular disorder&#xD;
&#xD;
          -  Any severe uncontrolled medical condition&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lobna OULDAMER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Teaching Hospital of Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecology Department, University Teaching Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>weight loss</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>energy metabolism</keyword>
  <keyword>Body mass index</keyword>
  <keyword>obesity</keyword>
  <keyword>muscle energy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

